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journal homepage: www.urol-sci .comEditorialRenal outcome after surgery for upper tract urothelial carcinomaAccurate staging in patients with upper tract urothelial carci-
noma (UTUC) is not easily achievable from preoperative work-up.
Thus, the preferred treatment for UTUC is based on radical neph-
roureterectomy (RNU) with bladder-cuff excision for the vast ma-
jority of patients.1 However; recent evidence has shown that the
loss of renal units by RNU is related to postoperative renal function
decline. This greatly reduces the possibility of receiving adjuvant
platinum-based chemotherapy if needed.2e5 Kaag et al6 conducted
a retrospective data review of 388 patients undergoing RNU from
four US institutions; they found that the mean estimated glomer-
ular ﬁltration rate (eGFR) decreased by 24% after surgery. Using a
cutoff of 60 mL/min/1.73 m2, 49% of patients were eligible for
chemotherapy before surgery, but only 19% of patients remained
eligible postoperatively. Using a cutoff of 45 mL/min/1.73 m2, 80%
of patients were eligible for chemotherapy preoperatively, but
only 55% remained eligible after surgery. In particular, patients of
old age (70 years) are more likely to experience a decline in renal
function after RNU. Based on this observation, they suggested neo-
adjuvant chemotherapy for patients with advanced stages of carci-
noma.6 Similar observations were concluded by Lane et al7 who
found a 21% median relative reduction in renal function, and fewer
than 50% of patients with sufﬁcient renal function to receive
platinum-based chemotherapy remain suitable postoperatively.
Although the rarity of UTUCmakes it a difﬁcult disease process to
study, a largemulti-institutional collaboration by the French Collab-
orative National Working-Group on UTUC and the UTUC collabora-
tion recently addressed most of the issues based on a Western
data pool.1,8 UTUC is reaching potentially epidemic proportions in
the East, especially in Taiwan and China, because of exposure to
carcinogenic herbal remedies.8e10 Data from China in the article by
Xiong et al11 using a 10-year study of a cohort of 785 cases attending
Peking University First Hospital from 2002 to 2011 demonstrated a
particularly high prevalence (58.6%) of chronic kidney disease
(CKD) in Chinese patients with UTUC and presenting 70.8% in the
group age 70 years and older. Moreover, the study results showed
that it is reasonable not to use serum creatinine alone to evaluate
renal function as it would overlook a large proportion of patients
with Stage 3 CKD in UTUCs, especially in those older than 70 years
(39.3% vs. 54.1%, p¼ 0.022).11 Due to the relatively higher prevalence
of CKD in Taiwan and China, a lot of the recent epidemiologic infor-
mation has pointed to aristolochic acid (AA). The molecular mecha-
nisms of AA nephropathy and interrelated UTUC were summarized
by Yang et al12 in a recent article. AA-induced renal damage involves
both tubular and interstitial injuries. In the acute phase, toxicity
causes proximal tubule injury whereas in the chronic phase the
apoptosis of the tubular epithelial cells, defective activation ofhttp://dx.doi.org/10.1016/j.urols.2015.05.001
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwantioxidative enzymes, mitochondrial damage, impaired regenera-
tion of proximal tubular epithelial cells, and interstitial cell prolifer-
ation lead to tubular atrophy and interstitial ﬁbrosis. The
aristolactams activated and the resultant formation of the AL-DNA
adducts in urothelial tissue lead to A:T to T:A transverse mutations
in the TP53 tumor suppression gene that is an important factor in
UTUC carcinogenesis. In addition to TP53 change, more and more
data indicate the importance of other candidate genes implicated
in this process; this information thus forms a ﬁngerprint for the
applicable diagnostic map to identify such patients with potential
renal function deterioration and synchronous/metachronous UTUC
formation.9,13
Pang et al in this issue of Urological Science report the Chang
Gang Memorial Hospital data regarding the longitudinal change
in renal function after RNU in patients with UTUC. They used a
retrospective study that included 186 patients, 87 men and 99
women, with a mean age of 67.2 years, who underwent unilateral
RNU between 1997 and 2001. Their cohort showed a preoperative
mean eGFR of 41.97 mL/min/1.73 m2. In total, 86.0% of the patients'
preoperative eGFR was less than 60 mL/min/1.73 m2. The mean
eGFR was 35.85 mL/min/1.73 m2 at the end of the 5-year follow
up. Of the 26 patients with normal preoperative renal function, 17
patients (65.4%) had new CKD. Ten patients (5.4%) required hemo-
dialysis at the end of the study. The authors concluded that the
average renal function of the patients with UTUC was not as good
as that in the general population. More than half of the patients
with normal renal function had new-onset CKD after surgery.
They suggest that in order to prevent further deterioration of renal
function, the feasibility of partial nephrectomy or segmental ureter-
ectomy should be reexamined for selected patients with localized
UTUC. In addition, neoadjuvant chemotherapy should be consid-
ered for those who are not good candidates for local treatment.
Though the data were only reﬂected in a large tertiary center
providing information in north Taiwan, they illustrate the entire
picture of UTUC faced in Taiwan. That is, relatively younger age, fe-
male sex, predominant and more profound renal function dimin-
ished in the patients with UTUC we treated. Taking the data
obtained from China and Taiwan, it is apparent that the UTUC pop-
ulation with renal function deterioration is a major public health
issue amongst ethnic Chinese. The progressive loss of renal function
post-RNU will lead to more patients with CKD and impede the
chance for chemotherapeutic treatment when needed and also in-
crease the number of end stage renal failure casualties. Perhaps it is
time to rethink the most appropriate surgical procedure for these
patients and not just burn down the house for every case with
UTUC.an LLC. Open access under CC BY-NC-ND license.
Editorial / Urological Science 26 (2015) 75e7676Kidney-sparing surgery (KSS) has the obvious advantage of
enabling preservation of renal function, ideally while maintaining
the oncological outcomes normally obtained after radical extirpa-
tive surgery. KSS is usually restricted to patients with imperative in-
dications such as renal insufﬁciency, solitary kidney, or bilateral
UTUC and patients who are medically unﬁt for RNU.3,14 However,
the favorable outcomes achieved with segmental ureterectomy
and endoscopic extirpation or fulguration ablation of the tumor
have encouraged several authors to propose the use of these proce-
dures in patients with UTUC who also have normal, functioning
contralateral kidneys. The elective indications for use of KSS in a
wider range of patients with UTUC have been deﬁned in recent
journals and warrants special attention.15,16
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